These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 17506719)

  • 21. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of diabetic nephropathy with angiotensin II blockers.
    Sonkodi S; Mogyorósi A
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v21-3. PubMed ID: 12817061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 1997 Dec; 15(7):S7-13. PubMed ID: 9532515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.
    Cohn JN
    Adv Ther; 2007; 24(6):1290-304. PubMed ID: 18165212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
    Hebert PR; Foody JM; Hennekens CH
    Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotensin pathway?
    Mandal AK; Hiebert LM
    Clin Nephrol; 2008 Mar; 69(3):169-78. PubMed ID: 18397715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
    Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for combining blockers of the renin-angiotensin system.
    Azizi M; Wuerzner G
    Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
    Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
    Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.
    ; Turnbull F; Neal B; Pfeffer M; Kostis J; Algert C; Woodward M; Chalmers J; Zanchetti A; MacMahon S
    J Hypertens; 2007 May; 25(5):951-8. PubMed ID: 17414657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.